Squawk on the Street

Anthropic IPO Opens Above $2 Trillion in Historic AI Market Debut

· Summarized

Share this episode
Anyone with this link can open it.
Share Link
Start at 0:00

Key takeaways

  • Anthropic priced at $83 and opened at $111.50, creating a fully diluted valuation above $2 trillion and making it a public pure-play frontier-AI company.
  • The company’s large cash raise is intended to support roughly $900 billion in future compute and infrastructure commitments, rather than simply provide excess liquidity.
  • Analysts and hosts see Anthropic’s strategic choice between licensing frontier models through APIs and using them internally to sell completed products or tasks as a central business question.
  • Vas Narasimhan says AI could reduce drug-development timelines from about 12 years to eight and improve clinical success, but he is more cautious than Dario Amodei about predicting cures for major diseases within a decade.
  • Anthropic’s founders and early employees receive extraordinary wealth, but the company’s founders have pledged 80% of their wealth to charity and the governance structure reserves equity for public-benefit causes.
  • Open-weight models are identified as a major competitive threat because many enterprise applications may not need the most advanced frontier models.

Summary

Anthropic’s expected opening and the mechanics of its IPO

The hosts introduce Anthropic’s trading debut as a record IPO that could make the nearly six-year-old company one of the world’s most valuable businesses. Leslie Picker reports an initial indication near $105 per share and explains that Morgan Stanley, acting as stabilization agent, is matching available sellers and buyers before Nasdaq opens the stock. Trading volume reaches $56 million against an offering of roughly 980 million shares. She also explains the 15% overallotment, or “green shoe,” which could raise another $12 billion if the stock performs well.

Why investors saw the IPO as positive despite a fragile tech market

Mike Santoli calls the deal’s financial reception a net positive because the capital raised helps fund Anthropic’s enormous future spending, but says the IPO could force institutions to bid above $100 for their desired positions and sell other technology stocks. Alex Kantrowitz says the market is asking whether Anthropic will remain an API provider or keep its best models in-house to build products. He highlights a possible conflict in life sciences: Anthropic could license models to drug developers while using its own wet lab to compete with them.

Frontier models may shift from selling tokens to selling completed tasks

The panel connects Anthropic’s strategy to Stan Druckenmiller’s prediction that frontier labs will move from selling tokens to selling tasks. Santoli argues that a valuation approaching $2 trillion implies Anthropic must eventually take business value from existing companies, even if the market is not strictly zero-sum. They point to the complicated “frenemy” ecosystem: Alphabet, Microsoft, Amazon, Nvidia, and others may own stakes or supply computing power while also competing for enterprise AI spending.

The hosts warn that a huge IPO valuation limits retail upside

The discussion compares Anthropic with Facebook, Nvidia, and SpaceX. Kantrowitz recalls buying Facebook early and seeing it rise roughly 16-fold, but says a 16-fold return from a potential $2 trillion Anthropic valuation would imply an implausible $32 trillion company. He argues that retail investors can still participate, but cannot expect the same asymmetric returns available to early private investors. Santoli adds that buyers must identify the assumptions behind the price, contrasting Anthropic’s uncertain growth with Meta’s expected $300 billion in revenue and established profitability.

Novartis CEO explains why he joined Anthropic’s board

Anthropic board member and Novartis CEO Vas Narasimhan says he joined because he supports a safe transition to an AI-enabled society and sees AI accelerating medicine and healthcare. He says Anthropic’s board has a safety committee and treats model-deployment risks as a central responsibility. Narasimhan favors structured AI regulation modeled partly on pharmaceuticals, while avoiding regulation that slows innovation unnecessarily. He expects AI to shorten drug-development timelines from about 12 years to eight and increase the share of medicines succeeding in clinical development from the industry’s roughly 8% average.

Narasimhan is more cautious than Anthropic’s CEO about curing disease

Asked whether frontier AI could cure cancer, Narasimhan says AI will first accelerate research, expand the number of diseases with meaningful treatments, and improve clinical success rates. He calls “cure” a big word because of the complexity of human biology. That is more restrained than Dario Amodei’s prediction that cancer, Alzheimer’s, heart disease, and mental illness could become relics in less than a decade. Narasimhan says that outcome would be remarkable if achieved, but prefers to promise more therapies and faster progress rather than a definitive cure.

The IPO creates extraordinary wealth and emphasizes Anthropic’s mission

Robert Frank reports that Anthropic’s seven founders could each be worth more than $20 billion and that employee equity grants total $232 billion, implying average employee wealth of about $44 million at the indicated price. He says at least 400 employees could become centimillionaires. The hosts discuss philanthropy as a possible counterweight to public anger over unequal AI benefits: the founders pledged 80% of their wealth to charity, and employees can donate shares through a matching program. Anthropic’s public-benefit structure reserves 5% of equity for public-benefit causes.

Demand, cash, and governance push the valuation above $2 trillion

Picker says Anthropic raised $81 billion through the marketed offering and $26 billion through private strategic placements, for $107 billion before a possible $12 billion green shoe. Pro forma cash could reach about $250 billion, important because the company has roughly $900 billion in future compute and infrastructure commitments and needs a strong credit profile. Institutional demand reportedly reached $400 billion against an initial $65 billion offering, with retail adding roughly $100 billion; about half of institutional orders received no allocation. The seven founders retain 50.1% of shareholder voting rights.

Anthropic opens at $111.50 and becomes a public AI bellwether

Anthropic finally opens at $111.50, roughly 34% above its $83 IPO price and above a $2 trillion fully diluted valuation. The hosts call it the first publicly traded pure-play frontier-model company and watch whether its shares hold the opening gain. Analyst Scott Berg initiates coverage with a $150 target, comparing AI’s potential labor disruption or augmentation to the internet’s expansion in the 1990s. He says falling compute costs could make profitability improve faster than expected, while open-weight models represent the larger competitive threat because many use cases will not require frontier capabilities.

Sponsors

  • Janus Henderson · Janus Henderson says it seeks better outcomes through insight-led investing, innovation for clients, and partnership. Jessica Lianzini, Head of Fixed Income Client Portfolio Management, says her role involves simplifying fixed income and helping clients achieve better outcomes.
  • State Street · State Street promotes sector ETFs as a way to gain exposure to leading companies without picking individual stocks. The ad notes that ETFs involve risk, including possible loss of principal, and directs listeners to read the prospectus.
  • VantageScore · VantageScore says traditional credit scores use only a limited snapshot, while VantageScore 4.0 uses 400% more credit and alternative data, including rental and utility payments. It says this brings five million mortgage-ready borrowers into the market and is used by Rocket Mortgage and nine of the ten largest banks.
  • Tommy John · Tommy John advertises soft, comfortable underwear, sleepwear, and loungewear, citing a 2026 Men's Health Editor's Choice designation. The offer is 40% off site-wide with code SXM.
  • OneTrust · OneTrust says its governance tools help organizations scale with speed as artificial intelligence expands, using the message: governance that helps you go.
  • State Street DIA ETF · State Street promotes DIA as the only ETF tracking the Dow, offering exposure to the growth potential of large-cap companies in one ETF. The ad warns of investment risk and possible loss of principal.

Show notes

November 19, 2026; 11am: Squawk on the Street covers Anthropic’s record IPO as shares open above a $2 trillion valuation and become a new pure-play AI market bellwether. The hour breaks down pricing, investor demand, governance, AI safety, compute spending, biotech use cases, wealth creation, and the broader implications for public markets.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account

Couldn't load the audio. A blocker may be stopping the show's tracking links. Open the file